Dados B3 › LJQQ3 × AMER3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | LJQQ3 | AMER3 | year |
|---|---|---|---|
| ROE | -34.1% | -5.6% | 2025 |
| ROIC | 2.1%! | 3.4% | 2025 |
| ROA | -4.3% | -1.6% | 2025 |
| Gross margin | 32.4% | 27.0% | 2025 |
| EBIT margin | 0.5% | 2.7% | 2025 |
| Net margin | -5.8% | -2.2% | 2025 |
| Net debt/EBITDA | -0.11x | 0.83x | 2025 |
| Current ratio | 1.61x | 1.67x | 2025 |
| Revenue growth (1y) | 4.6% | -1.2% | 2025 |
| Revenue growth (5y CAGR) | 11.5% | 4.0% | 2025 |
| Piotroski F-Score | 4/9 | 3/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | LJQQ3 | AMER3 | year |
|---|---|---|---|
| P/E | -2.66x | -3.81x | 2025 |
| P/B | 1.06x | 0.22x | 2025 |
| EV/EBITDA | 2.63x | 1.73x | 2025 |
| FCF yield | 25.5% | 34.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:11 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it